Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Acetaminophen (oral dosage form, suppositories)

Tramadol hydrochloride/acetaminophen

Salicylamide/acetaminophen/anhydrous caffeine/chlorpheniramine maleate

Salicylamide/acetaminophen/anhydrous caffeine/promethazine methylenedisalicylate

Diprophylline/dihydrocodeine phosphate/dl−methylephedrine hydrochloride/diphenhydramine salicylate/acetaminophen/bromovalerylurea

January 17, 2023

Therapeutic category

Antipyretics, analgesics and anti-inflammatory agents

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Agents used for common cold

Antitussives

Non-proprietary name

Acetaminophen

Tramadol hydrochloride/acetaminophen

Salicylamide/acetaminophen/anhydrous caffeine/chlorpheniramine maleate

Salicylamide/acetaminophen/anhydrous caffeine/promethazine methylenedisalicylate

Diprophylline/dihydrocodeine phosphate/dl−methylephedrine hydrochloride/diphenhydramine salicylate/acetaminophen/bromovalerylurea

Safety measure

Precautions should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
Adverse Reactions Clinically Significant Adverse Reactions (N/A)	Adverse Reactions Clinically Significant Adverse Reactions <u>Drug-induced hypersensitivity syndrome:</u> <u>Initial symptoms of rash and pyrexia, followed by serious delayed symptoms of hypersensitivity accompanied by hepatic impairment, swollen lymph nodes, increased white blood cell, eosinophilia, and appearance of atypical lymphocytes may occur. Symptoms are often accompanied by virus reactivation, such as human herpes virus type 6 (HHV-6). Caution is required for recurrence or prolongation of rash, pyrexia, and hepatic impairment, etc. that may occur even after discontinuation of administration.</u>

Note: Salicylamide/acetaminophen/anhydrous caffeine/chlorpheniramine maleate is designated as a product requiring preparation of a Drug Guide for Patients.

N/A: Not Applicable. No corresponding language is included in the current Precautions.

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Drug-induced hypersensitivity syndrome</u>

	Initial symptoms of rash and pyrexia, followed by serious delayed symptoms of hypersensitivity accompanied by hepatic impairment, swollen lymph nodes, increased white blood cell, eosinophilia, and appearance of atypical lymphocytes may occur. Symptoms are often accompanied by virus reactivation, such as human herpes virus type 6 (HHV-6). Caution is required for recurrence or prolongation of rash, pyrexia, and hepatic impairment, etc. that may occur even after discontinuation of administration.

Note: Salicylamide/acetaminophen/anhydrous caffeine/chlorpheniramine maleate is designated as a product requiring preparation of a Drug Guide for Patients.

N/A: Not Applicable. No corresponding language is included in the current Precautions.